Age-Related Vision Dysfunction Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major age-related vision dysfunction markets reached a value of US$ 63.0 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 85.1 Million by 2034, exhibiting a growth rate (CAGR) of 2.76% during 2024-2034.
The age-related vision dysfunction market has been comprehensively analyzed in IMARC's new report titled "Age-Related Vision Dysfunction Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Age-related vision dysfunction refers to a range of visual impairments that commonly manifest as people grow older. It is a natural part of the aging process and can impact various aspects of visual function. The common symptoms often include diminished visual acuity, decreased ability to focus on close objects (presbyopia), reduced contrast sensitivity, and increased susceptibility to glare and night vision difficulties. These issues can significantly affect daily activities, such as reading, driving, and recognizing faces. Diagnosis of the ailment involves comprehensive eye examinations conducted by qualified optometrists or ophthalmologists. These investigations assess factors like visual acuity, refraction, and the health of the eye's internal structures, including the lens and retina. Tonometry may also be performed to measure intraocular pressure, helping to detect glaucoma, a condition often associated with aging eyes. Additionally, specialized tests might be conducted to evaluate contrast sensitivity and visual field, which can provide a thorough understanding of the patient's visual capabilities.
The expanding geriatric population, who are susceptible to retinal detachment, in which the gel-like vitreous inside the eye may shrink and pull away from the retina, leading to floaters and flashes, is primarily driving the age-related vision dysfunction market. In addition to this, the inflating utilization of potent medications, such as antioxidants, anti-VEGF injections, anti-inflammatory agents, etc., to control disease progression and mitigate symptoms is also creating a positive outlook for the market. Moreover, the widespread adoption of corrective surgical interventions, including cataract removal and lens replacement surgeries, is further bolstering the market growth. Apart from this, the rising usage of rehabilitative visual therapies, as they aid in maximizing the remaining vision, enhancing visual adaptation, and facilitating better daily living skills, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of gene therapy, which emphasizes introducing or modifying genetic material in cells to rectify or replace the deteriorating genes linked to vision loss, is also augmenting the market growth. Furthermore, the escalating demand for innovative technologies, such as retinal implants and artificial vision systems, since they hold the potential to restore partial vision in patients with severe visual impairments, is expected to drive the age-related vision dysfunction market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the age-related vision dysfunction market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for age-related vision dysfunction and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the age-related vision dysfunction market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the age-related vision dysfunction market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the age-related vision dysfunction market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current age-related vision dysfunction marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the age-related vision dysfunction market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the age-related vision dysfunction market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the age-related vision dysfunction market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of age-related vision dysfunction across the seven major markets?
What is the number of prevalent cases (2018-2034) of age-related vision dysfunction by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of age-related vision dysfunction by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with age-related vision dysfunction across the seven major markets?
What is the size of the age-related vision dysfunction patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of age-related vision dysfunction?
What will be the growth rate of patients across the seven major markets?
Age-Related Vision Dysfunction: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for age-related vision dysfunction drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the age-related vision dysfunction market?
What are the key regulatory events related to the age-related vision dysfunction market?
What is the structure of clinical trial landscape by status related to the age-related vision dysfunction market?
What is the structure of clinical trial landscape by phase related to the age-related vision dysfunction market?
What is the structure of clinical trial landscape by route of administration related to the age-related vision dysfunction market?
The age-related vision dysfunction market has been comprehensively analyzed in IMARC's new report titled "Age-Related Vision Dysfunction Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Age-related vision dysfunction refers to a range of visual impairments that commonly manifest as people grow older. It is a natural part of the aging process and can impact various aspects of visual function. The common symptoms often include diminished visual acuity, decreased ability to focus on close objects (presbyopia), reduced contrast sensitivity, and increased susceptibility to glare and night vision difficulties. These issues can significantly affect daily activities, such as reading, driving, and recognizing faces. Diagnosis of the ailment involves comprehensive eye examinations conducted by qualified optometrists or ophthalmologists. These investigations assess factors like visual acuity, refraction, and the health of the eye's internal structures, including the lens and retina. Tonometry may also be performed to measure intraocular pressure, helping to detect glaucoma, a condition often associated with aging eyes. Additionally, specialized tests might be conducted to evaluate contrast sensitivity and visual field, which can provide a thorough understanding of the patient's visual capabilities.
The expanding geriatric population, who are susceptible to retinal detachment, in which the gel-like vitreous inside the eye may shrink and pull away from the retina, leading to floaters and flashes, is primarily driving the age-related vision dysfunction market. In addition to this, the inflating utilization of potent medications, such as antioxidants, anti-VEGF injections, anti-inflammatory agents, etc., to control disease progression and mitigate symptoms is also creating a positive outlook for the market. Moreover, the widespread adoption of corrective surgical interventions, including cataract removal and lens replacement surgeries, is further bolstering the market growth. Apart from this, the rising usage of rehabilitative visual therapies, as they aid in maximizing the remaining vision, enhancing visual adaptation, and facilitating better daily living skills, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of gene therapy, which emphasizes introducing or modifying genetic material in cells to rectify or replace the deteriorating genes linked to vision loss, is also augmenting the market growth. Furthermore, the escalating demand for innovative technologies, such as retinal implants and artificial vision systems, since they hold the potential to restore partial vision in patients with severe visual impairments, is expected to drive the age-related vision dysfunction market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the age-related vision dysfunction market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for age-related vision dysfunction and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the age-related vision dysfunction market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the age-related vision dysfunction market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the age-related vision dysfunction market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current age-related vision dysfunction marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the age-related vision dysfunction market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the age-related vision dysfunction market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the age-related vision dysfunction market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of age-related vision dysfunction across the seven major markets?
What is the number of prevalent cases (2018-2034) of age-related vision dysfunction by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of age-related vision dysfunction by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with age-related vision dysfunction across the seven major markets?
What is the size of the age-related vision dysfunction patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of age-related vision dysfunction?
What will be the growth rate of patients across the seven major markets?
Age-Related Vision Dysfunction: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for age-related vision dysfunction drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the age-related vision dysfunction market?
What are the key regulatory events related to the age-related vision dysfunction market?
What is the structure of clinical trial landscape by status related to the age-related vision dysfunction market?
What is the structure of clinical trial landscape by phase related to the age-related vision dysfunction market?
What is the structure of clinical trial landscape by route of administration related to the age-related vision dysfunction market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 AGE-RELATED VISION DYSFUNCTION - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 AGE-RELATED VISION DYSFUNCTION - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 AGE-RELATED VISION DYSFUNCTION - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Diagnosed Cases (?2018-2034?)
7.2.6 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Diagnosed Cases (?2018-2034?)
7.3.6 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Diagnosed Cases (?2018-2034?)
7.4.6 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Diagnosed Cases (?2018-2034?)
7.5.6 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Diagnosed Cases (?2018-2034?)
7.6.6 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Diagnosed Cases (?2018-2034?)
7.7.6 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Diagnosed Cases (?2018-2034?)
7.8.6 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Diagnosed Cases (?2018-2034?)
7.9.6 Patient Pool/Treated Cases (?2018-2034?)
8 AGE-RELATED VISION DYSFUNCTION - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 AGE-RELATED VISION DYSFUNCTION - UNMET NEEDS
10 AGE-RELATED VISION DYSFUNCTION - KEY ENDPOINTS OF TREATMENT
11 AGE-RELATED VISION DYSFUNCTION - MARKETED PRODUCTS
11.1 List of Age-Related Vision Dysfunction Marketed Drugs Across the Top 7 Markets
11.1.1 Vuity (Pilocarpine Hydrochloride Ophthalmic Solution) - Allergan
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Lucentis (Ranibizumab Injection) - Genentech/Novartis Ophthalmics
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Vabysmo (Faricimab-Svoa) - Genentech
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
11.1.4 Macugen (Pegaptanib Sodium Injection) - Pfizer
11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Regulatory Status
11.1.4.4 Clinical Trial Results
11.1.4.5 Sales Across Major Markets
11.1.5 Beovu (Brolucizumab) - Novartis
11.1.5.1 Drug Overview
11.1.5.2 Mechanism of Action
11.1.5.3 Regulatory Status
11.1.5.4 Clinical Trial Results
11.1.5.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 AGE-RELATED VISION DYSFUNCTION - PIPELINE DRUGS
12.1 List of Age-Related Vision Dysfunction Pipeline Drugs Across the Top 7 Markets
12.1.1 Drug Name – Company Name
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the complete list of pipeline drugs has been provided in the report.
13. AGE-RELATED VISION DYSFUNCTION - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. AGE-RELATED VISION DYSFUNCTION – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 AGE-RELATED VISION DYSFUNCTION - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Age-Related Vision Dysfunction - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Age-Related Vision Dysfunction - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Age-Related Vision Dysfunction - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Age-Related Vision Dysfunction - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Age-Related Vision Dysfunction - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Age-Related Vision Dysfunction - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Age-Related Vision Dysfunction - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Age-Related Vision Dysfunction - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Age-Related Vision Dysfunction - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Age-Related Vision Dysfunction - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Age-Related Vision Dysfunction - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Age-Related Vision Dysfunction - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Age-Related Vision Dysfunction - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Age-Related Vision Dysfunction - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Age-Related Vision Dysfunction - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Age-Related Vision Dysfunction - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Age-Related Vision Dysfunction - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Age-Related Vision Dysfunction - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Age-Related Vision Dysfunction - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Age-Related Vision Dysfunction - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Age-Related Vision Dysfunction - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Age-Related Vision Dysfunction - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Age-Related Vision Dysfunction - Access and Reimbursement Overview
16 AGE-RELATED VISION DYSFUNCTION - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 AGE-RELATED VISION DYSFUNCTION MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 AGE-RELATED VISION DYSFUNCTION MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 AGE-RELATED VISION DYSFUNCTION - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 AGE-RELATED VISION DYSFUNCTION - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 AGE-RELATED VISION DYSFUNCTION - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Diagnosed Cases (?2018-2034?)
7.2.6 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Diagnosed Cases (?2018-2034?)
7.3.6 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Diagnosed Cases (?2018-2034?)
7.4.6 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Diagnosed Cases (?2018-2034?)
7.5.6 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Diagnosed Cases (?2018-2034?)
7.6.6 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Diagnosed Cases (?2018-2034?)
7.7.6 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Diagnosed Cases (?2018-2034?)
7.8.6 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Diagnosed Cases (?2018-2034?)
7.9.6 Patient Pool/Treated Cases (?2018-2034?)
8 AGE-RELATED VISION DYSFUNCTION - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 AGE-RELATED VISION DYSFUNCTION - UNMET NEEDS
10 AGE-RELATED VISION DYSFUNCTION - KEY ENDPOINTS OF TREATMENT
11 AGE-RELATED VISION DYSFUNCTION - MARKETED PRODUCTS
11.1 List of Age-Related Vision Dysfunction Marketed Drugs Across the Top 7 Markets
11.1.1 Vuity (Pilocarpine Hydrochloride Ophthalmic Solution) - Allergan
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Lucentis (Ranibizumab Injection) - Genentech/Novartis Ophthalmics
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Vabysmo (Faricimab-Svoa) - Genentech
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
11.1.4 Macugen (Pegaptanib Sodium Injection) - Pfizer
11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Regulatory Status
11.1.4.4 Clinical Trial Results
11.1.4.5 Sales Across Major Markets
11.1.5 Beovu (Brolucizumab) - Novartis
11.1.5.1 Drug Overview
11.1.5.2 Mechanism of Action
11.1.5.3 Regulatory Status
11.1.5.4 Clinical Trial Results
11.1.5.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 AGE-RELATED VISION DYSFUNCTION - PIPELINE DRUGS
12.1 List of Age-Related Vision Dysfunction Pipeline Drugs Across the Top 7 Markets
12.1.1 Drug Name – Company Name
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the complete list of pipeline drugs has been provided in the report.
13. AGE-RELATED VISION DYSFUNCTION - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. AGE-RELATED VISION DYSFUNCTION – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 AGE-RELATED VISION DYSFUNCTION - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Age-Related Vision Dysfunction - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Age-Related Vision Dysfunction - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Age-Related Vision Dysfunction - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Age-Related Vision Dysfunction - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Age-Related Vision Dysfunction - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Age-Related Vision Dysfunction - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Age-Related Vision Dysfunction - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Age-Related Vision Dysfunction - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Age-Related Vision Dysfunction - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Age-Related Vision Dysfunction - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Age-Related Vision Dysfunction - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Age-Related Vision Dysfunction - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Age-Related Vision Dysfunction - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Age-Related Vision Dysfunction - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Age-Related Vision Dysfunction - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Age-Related Vision Dysfunction - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Age-Related Vision Dysfunction - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Age-Related Vision Dysfunction - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Age-Related Vision Dysfunction - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Age-Related Vision Dysfunction - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Age-Related Vision Dysfunction - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Age-Related Vision Dysfunction - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Age-Related Vision Dysfunction - Access and Reimbursement Overview
16 AGE-RELATED VISION DYSFUNCTION - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 AGE-RELATED VISION DYSFUNCTION MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 AGE-RELATED VISION DYSFUNCTION MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
